Clinical Trial

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

Study acronym: BOREALIS-1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-06-06; most recent amendment 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2025-07-29
Trial Details
NCT Number NCT07021898
Lead Sponsor Erasca, Inc.
Conditions Metastatic Solid Tumors
Enrollment 200 participants
Start Date 2025-08-06
Primary Completion 2028-08 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-03